James Brian Windsor
CEO, President & DirectorDr. James Brian Windsor, Ph.D. is Chief Executive Officer and Director of Rein Therapeutics Inc. (formerly known as Aileron Therapeutics, Inc.) from March 11, 2024 and its President since October 2023. Dr. Windsor served as Chief Operating Officer from October 2023 until March 11, 2024. He had been a Director of TFF Pharmaceuticals, Inc. since January 2018 until March 21, 2022 and served as its Chief Science Officer from September 2019 until March 21, 2022. Dr. Windsor was the President, Chief Executive Officer and a member of the board of directors of Lung Therapeutics, positions he had held since July 2013 to October 2023. He served as the Chief Scientist at Entercel, Ltd. and was later appointed as Entercel’s Managing Director. From November 2009 to March 2013, Dr. Windsor served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies, Inc., an early-stage technology venture creation and management company, where he served as Managing Director or President for ten portfolio companies. During his time at Emergent Technologies, Inc. (ETI), Dr. Windsor served as Managing Director for 10 of ETI's portfolio companies and was part of ETI’s Strategic Planning Group. Dr. Windsor is also a Managing Director at Entercel, Ltd. and at Auxano Biologics, Ltd. and Selenium, Ltd. Prior to joining ETI, Dr. Windsor was a Founder and Vice President of Research and Development for Texagen, Inc. His graduate work on cell transport modulation in the laboratory of Professor Alan Lloyd helped lead to the development of technology licensed by Entercel, Ltd. Dr. Windsor is a co-inventor on 15 patents. He holds a Ph.D. in Molecular Biology from The University of Texas at Austin, earned in 2000 and is an invited speaker for both scientific and technology transfer events. He is also an inventor on multiple patents and patent applications.
Positions
- Company NameRein Therapeutics Inc.Stock CodeRNTXPositionCEO, President & DirectorColleagues
- JHJosef H. von RickenbachIndependent Chairman
- TMTimothy M. CunninghamInterim CFO & Principal Accounting Officer
- CMCory M. HogaboamChief Scientific Officer
- JFJennifer FaigleCounsel
- RCRon ChenVP of Finance and Corporate Controller
- RJReinhard J. AmbrosIndependent Lead Director
- AAAlan A. MussoIndependent Director
- WCWilliam Carl FaireyIndependent Director
